en en fi en en en en en fr en en en en en en en en en en en en en en en en en en en en en he en en en en en en en en en en en ro it en eu en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en it en en en en en en en en en en en
“StarGuide allows us to acquire the patient’s data in the best conditions,” explains Gilles Le Rouzic, Medical Physicist, Hospital of Orleans, France. “The pixelated CZT modules combined with registered Dual-Channel tungsten collimation also contribute to improved resolution and sensitivity compared to conventional SPECT/CT. Every test we’ve conducted thus far shows better results than a standard NaI camera. All in all, the shape adaptive gantry of this new device is innovative by its very nature.”
Before performing a SPECT/CT, a clinician administers very small amounts of radioactive materials (radiopharmaceuticals) which releases radioactive emissions that are detected by the CZT detectors and processed into images. Compared to conventional technologies, CZT detectors offer improved SPECT sensitivity and resolution of these emissions, which in turn helps clinicians pinpoint the size, shape, and position of lesions with exceptional accuracy. Paired with innovative reconstruction, the resulting images provide outstanding quantification for the diagnosis and staging of disease and monitoring of treatment.
Traditionally, only one tracer could be imaged at a time, but the excellent energy resolution of the GE Healthcare-produced CZT crystals for StarGuide’s Digital Focus Detectors offers clinicians the unique ability to simultaneously image multiple tracers in a single scan. This ability helps reduce the need for multiple patient visits and, in relevant cases, multiple patient sedations. Also, the inherent temporal registration between the images helps increase clinicians’ confidence in differential diagnosis.
Finally, the combination of StarGuide’s shape adaptive gantry and CZT detector technology supports the imaging of tracers used in theragnostic with impressive quality. This includes Lutetium-177 (177Lu), a tracer used to diagnose and evaluate a patient’s treatment response for neuroendocrine and prostate cancer. 177Lu is currently not an FDA-approved tracer.
While there is still much work to be done in the field of theragnostic and precision health, StarGuide offers clinicians unique opportunities to make personalized care decisions and treatment response assessments that are at the heart of theranostics. GE Healthcare is uniquely positioned to advance these efforts as the only partner with solutions spanning from pharmaceutical diagnostics, cyclotrons, chemistry synthesis, PET/CT, PET/MR, nuclear medicine, advanced digital solutions and pharma partnerships to cover the breadth of steps from discovery to diagnosis to treatment.
Nuclear Medicine Prepares for Greater 68Ga Demand
When the US Food and Drug Administration (FDA) approved the use...
The Promise of Nuclear Medicine: Developing Cancer Detection and Treatment with Molecularly Targeted Radiation (MTR)